WAS
EVFM

WESPAC Advisors SoCal’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

WESPAC Advisors SoCal’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11
Closed – – 343
2019
Q1 		$0 Hold
11
– – ﹤0.01% 368
2018
Q4 		$0 Hold
11
– – ﹤0.01% 376
2018
Q3 		$0 Buy
+11
New +$476 ﹤0.01% 321
2018
Q2 		– Sell
-33
Closed -$3K – 270
2018
Q1 		$3K Hold
33
– – ﹤0.01% 241
2017
Q4 		$5K Hold
33
– – ﹤0.01% 217
2017
Q3 		$1K Hold
33
– – ﹤0.01% 262
2017
Q2 		$1K Hold
33
– – ﹤0.01% 238
2017
Q1 		$4.8K Hold
33
– – ﹤0.01% 213
2016
Q4 		$3.36K Hold
33
– – ﹤0.01% 225
2016
Q3 		$3.36K Hold
33
– – ﹤0.01% 235
2016
Q2 		$2.94K Hold
33
– – ﹤0.01% 249
2016
Q1 		$1.83K Hold
33
– – ﹤0.01% 263
2015
Q4 		$4K Buy
+33
New +$21.8K ﹤0.01% 227

Other funds holding EVFM

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

WESPAC Advisors SoCal's EVFM Position: Q2 2019 in Review

WESPAC Advisors SoCal sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2019, closing a stake of 11 shares.

WESPAC Advisors SoCal first reported a position in EVFM in Q4 2015 and held it in 13 quarters. The position peaked at $5K in Q4 2017. 36 funds tracked by Wall St. Rank hold EVFM as of Q2 2019.

  • WESPAC Advisors SoCal reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • WESPAC Advisors SoCal sold 11 Evofem Biosciences, Inc. Common Stock shares in Q2 2019.
  • WESPAC Advisors SoCal first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2015 and held it in 13 quarters.
  • WESPAC Advisors SoCal's Evofem Biosciences, Inc. Common Stock position peaked at $5K in Q4 2017.
  • 36 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2019.

Based on WESPAC Advisors SoCal's 13F filing for Q2 2019, filed 30 Jul 2019.